Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Publication of Annual Report and Accounts and Notice of Annual General Meeting
Winsford, UK – 18 May 2020: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Annual Report and Financial Statements for the year ended 31 December 2019 and Notice of Annual General Meeting were posted to shareholders today and are available on the Investor Relations section of the Group’s website.
Annual General Meeting
In line with the UK Government’s latest guidelines on COVID-19, AMS will host its AGM as a closed meeting at the Group’s Winsford office at 11.00 am on 10 June 2020. The health and safety of the Group’s shareholders as well as its employees and customers is of paramount importance and, as a result, it will not be possible for shareholders to attend the meeting in person. Any shareholders attempting to attend the AGM will be refused entry.
The Annual General Meeting notice and proxy forms were posted to shareholders today and are available on the Group’s website at www.admedsol.com/investor-relations. The AGM will be convened with the minimum necessary quorum of two shareholders. The outcome of the resolutions will as usual be determined by shareholder vote based on the proxy votes received. Shareholders are therefore strongly encouraged to vote by proxy on the resolutions contained in the AGM notice. Given the restrictions on attendance, shareholders are also strongly encouraged to appoint the “Chairman of the Meeting” as their proxy rather than another person who will not be permitted to attend the meeting. To ensure votes are counted at the AGM, completed proxy forms should be returned to: Link Asset Services, PXS, 34 Beckenham Road, Beckenham, Kent, BR3 4TU and must be received by 11.00 am on 8 June 2020 in order to be valid. This is particularly important given that COVID-19 has caused delays to the collection and delivery of postal services.
The results of the AGM will be announced to the London Stock Exchange and placed on the Group’s website, in the usual way, as soon as practicable after the conclusion of the AGM.
Non-Executive Board Succession Planning and Change
AMS has a well-established and mature Non-Executive Board which has successfully overseen the growth of the Group over recent years. Despite the benefits this brings, the Board are aware of the importance of succession planning.
A plan has been initiated to refresh the Non-Executive Directors on the Board and this process will start with Peter Steinmann retiring from the Board at the AGM this year. The Board would like to thank Peter for his contribution over the last six and a half years.
A process is underway to seek a replacement for Peter.
In line with the 2018 UK Corporate Governance Code Provision 24 and best practice, Peter Allen stepped down from the Audit Committee with effect from 6 May 2020. When invited, he will attend Audit Committee meetings as the Board considers his extensive accounting experience adds value to the discussion. Following this change the Audit Committee comprises Stephen Bellamy (Chair), Penny Freer and Peter Steinmann. Peter Steinmann will be a member of the Audit Committee until he retires from the Board at the AGM.
The Board would like to take this opportunity to thank all shareholders for their continued support and understanding in these exceptional circumstances and wish them well during this time.
– End –
For further information, please contact:
Advanced Medical Solutions Group plc
Tel: 44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications
Tel: 44 (0) 20 3709 5700
Mary-Jane Elliott / Matthew Neal / Olivia Manser
Investec Bank PLC (NOMAD & Broker)
Tel: 44 (0) 20 7597 5970
Daniel Adams / Patrick Robb / Gary Clarence
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.
AMS’s products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.